Physician profile
Mark H Gregory
NPI 1104843663
$4,958.12
in general payments reported to CMS, 2019-2025
30 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $604 · 2021: $548 · 2022: $281 · 2023: $274 · 2024: $1,083 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,487.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $799.81 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $686.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $683.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $357.46 | 2019-2021 | |
| Pfizer INC. | $332.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $308.53 | 2020-2025 | |
| Novo Nordisk INC | $288.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $182.38 | 2019-2022 | |
| Abbvie INC. | $152.68 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.43 | 2020-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $129.08 | 2020-2021 | |
| Cleerly, INC. | $121.63 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kowa Pharmaceuticals America, INC. | $105.68 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $102.32 | 2019-2025 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $95.93 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62.50 | 2023-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $58.99 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $54.93 | 2025 | Nexletol |
| Boston Scientific Corporation | $39.93 | 2019-2022 | |
| Heartflow, INC. | $37.42 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.54 | 2022 | |
| Corcept Therapeutics | $36.38 | 2022-2024 | Korlym |
| Exact Sciences Corporation | $35.16 | 2024-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $27.46 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2024 | Jardiance, Synjardy |
| Idorsia Pharmaceuticals US INC | $14.57 | 2022 | |
| Glaxosmithkline, LLC. | $14.48 | 2019 | |
| Seqirus USA INC | $14.39 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $13.71 | 2025 | |
| Allergan, INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.